source
- GSK halts Phase 3 chronic cough drug camlipixant, jeopardizing $2 billion Bellus Health acquisitionGSK announced it is ending development of camlipixant, a drug aimed at treating refractory chronic cough, after completing Phase 3 trials. The move comes as the company proceeds with its planned $…
- Bolton Medical Issues Urgent Recall of Relay Pro Thoracic Stent Graft Over Unclasping FaultBolton Medical announced an urgent Class I recall of its Relay Pro Thoracic Stent Graft System, specifically the non-bare stent configuration 32 mm and larger. The recall was triggered because the…